Amantadine in the treatment of Parkinson's disease and other movement disorders
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amantadine in the treatment of Parkinson's disease and other movement disorders
Authors
Keywords
-
Journal
LANCET NEUROLOGY
Volume 20, Issue 12, Pages 1048-1056
Publisher
Elsevier BV
Online
2021-10-22
DOI
10.1016/s1474-4422(21)00249-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials
- (2021) Wojciech Danysz et al. JOURNAL OF NEURAL TRANSMISSION
- Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study
- (2020) Olivier Rascol et al. DRUGS & AGING
- Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine
- (2020) Weixing Shen et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial
- (2020) Bardia Nourbakhsh et al. LANCET NEUROLOGY
- Recent Advances in the Pharmacology of Tardive Dyskinesia
- (2020) Stanley N. Caroff Clinical Psychopharmacology and Neuroscience
- Antiviral amantadine
- (2019) Taha Nisar et al. LANCET NEUROLOGY
- Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
- (2018) Robert A. Hauser et al. CLINICAL PHARMACOKINETICS
- Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
- (2018) Lawrence W. Elmer et al. CNS DRUGS
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
- (2018) Susan H. Fox et al. MOVEMENT DISORDERS
- Practice guideline update recommendations summary: Disorders of consciousness
- (2018) Joseph T. Giacino et al. NEUROLOGY
- Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts
- (2018) Alberto J. Espay et al. ANNALS OF NEUROLOGY
- Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)
- (2017) Wolfgang Oertel et al. MOVEMENT DISORDERS
- An updated meta-analysis of amantadine for treating dyskinesia in Parkinson’s disease
- (2017) Min Kong et al. Oncotarget
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
- (2017) Rajesh Pahwa et al. JAMA Neurology
- Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies
- (2016) Robert A. Hauser et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Mavoglurant in Parkinson's patients withl-Dopa-induced dyskinesias: Two randomized phase 2 studies
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients
- (2016) Simone Schächtele et al. PLoS One
- Freezing of gait: a practical approach to management
- (2015) Jorik Nonnekes et al. LANCET NEUROLOGY
- Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
- (2015) Rajesh Pahwa et al. MOVEMENT DISORDERS
- Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease
- (2014) Wai Kin D. Ko et al. MOVEMENT DISORDERS
- Evaluating the effects of amantadin, modafinil and acetyl-l-carnitine on fatigue in multiple sclerosis – result of a pilot randomized, blind study
- (2013) Alenka Horvat Ledinek et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Safety of Perioperative Treatment With Intravenous Amantadine in Patients With Parkinson Disease
- (2013) Aeyal Raz et al. CLINICAL NEUROPHARMACOLOGY
- Intravenous amantadine on freezing of gait in Parkinson’s disease: a randomized controlled trial
- (2013) Jee Young Lee et al. JOURNAL OF NEUROLOGY
- Which dyskinesia scale best detects treatment response?
- (2013) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
- (2013) Erwan Bezard et al. MOVEMENT DISORDERS
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- (2013) F. Ory-Magne et al. NEUROLOGY
- Amantadine for Freezing of Gait in Patients With Parkinson Disease
- (2012) Roneil Malkani et al. CLINICAL NEUROPHARMACOLOGY
- Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
- (2012) Susan Duty CNS DRUGS
- Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
- (2012) J. J. Ferreira et al. EUROPEAN JOURNAL OF NEUROLOGY
- Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study
- (2012) Vahid Shaygannejad et al. NEUROLOGICAL RESEARCH
- Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology
- (2012) M. J. Armstrong et al. NEUROLOGY
- Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury
- (2012) Joseph T. Giacino et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels
- (2011) Simone Bido et al. JOURNAL OF NEUROCHEMISTRY
- Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
- (2011) Christopher Kobylecki et al. MOVEMENT DISORDERS
- Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia
- (2011) Bernardino Ossola et al. NEUROPHARMACOLOGY
- The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine
- (2011) Christian Sommerauer et al. NEUROPHARMACOLOGY
- Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study
- (2010) Daniel Weintraub et al. ANNALS OF NEUROLOGY
- Pathological gambling in Parkinson disease is reduced by amantadine
- (2010) Astrid Thomas et al. ANNALS OF NEUROLOGY
- Effects of Amantadine on Tardive Dyskinesia
- (2010) Sofia Pappa et al. CLINICAL NEUROPHARMACOLOGY
- A brief history of levodopa
- (2010) Oleh Hornykiewicz JOURNAL OF NEUROLOGY
- Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
- (2010) Paolo Calabresi et al. LANCET NEUROLOGY
- Long-term antidyskinetic efficacy of amantadine in Parkinson's disease
- (2010) Elisabeth Wolf et al. MOVEMENT DISORDERS
- Prescribing patterns of antiparkinsonian agents in Europe
- (2010) Mário Miguel Rosa et al. MOVEMENT DISORDERS
- Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study
- (2010) Karla Eggert et al. MOVEMENT DISORDERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now